• 

  Hyperbole, Misinfo: Alzheimer’s Experts Say Recent Amyloid Fraud Claims Get It All Wrong 
• 

  FDA Fast-Tracks Alzheimer’s Drug Lecanemab; Decision Expected By Early 2023
• 

  Vaxxinity Wants to ‘Democratize’ Alzheimer’s Treatment With Vaccine
• 

  FDA Ups ARIA Monitoring for Aduhelm; Doubles MRI Requirement
• 

  PPA: Alzheimer’s-Like Brain Changes Don’t Always Bring Memory Loss
• 

  Oligodendrocytes and Myelin: Distracting Microglia in Alzheimer’s
• 

  Meet Microglia, the Brain’s Alzheimer’s-Fighting Sculptors
• 

  Where’s Our Alzheimer’s Cure? Karl Herrup on What’s Taking So Long
• 

  Amyloid Hypothesis Twist: Restoring ‘Good’ Beta-Amyloid to Treat Alzheimer’s
• 

  Amyloid Hypothesis in the Hot Seat After Aduhelm Approved for Alzheimer’s
• 

  Aducanumab Approved: U.S. FDA Gives Biogen Alzheimer’s Drug Approval
• 

  Exploring Stem Cell Therapies for Alzheimer’s Treatment
• 

  What’s Next for Eli Lilly Alzheimer’s Drug Donanemab? Trial Enrollment Continues
• 

  Why AC Immune’s Alzheimer’s Vaccine Failed Phase 2 Trials, and What’s Next
• 

  Experimental Alzheimer’s Drug Donanemab Looks Promising in Phase 2 Trial

Previous123Next